AstraZeneca's Incubutor at the Boston BioHub announces on-boarding of sRNAlytics
AstraZeneca’s Incubator at the Boston BioHub is excited to announce the arrival of sRNAlytics, its second company to on-board as a life science incubator resident. As a resident, sRNAlytics will benefit from free access to state-of-the-art laboratory facilities and equipment as well as access to mentoring from AZ and other resident company scientists within the vibrant research hub.
sRNAlytics developed a computational platform that combines Next-Generation Sequencing with big data analytics and machine learning to uncover small RNA biomarkers of disease. Their flagship program sRNA-TypeHD is a panel of small RNA biomarkers that can detect and monitor Huntington’s Disease up to 12 years before symptomatic onset. They are starting development of their next product sRNA-TypeD, a biomarker panel to diagnose and monitor progression of Alzheimer’s and Parkinson’s Disease.
“The campus at 35 Gatehouse Drive is pristine, and the BioHub has a great vibe among the resident companies. We’re honored and excited to have been selected by AstraZeneca to join the Incubator. We’re looking forward to the opportunity to partner with AstraZeneca and take sRNAlytics to the next phase,” said Dr. Salzman, Founder and CEO.
AstraZeneca’s Incubator expects two additional companies to on-board in the fall. Applications to join AstraZeneca’s Incubator are evaluated on a rolling admission basis.